November 18, 2026

|

Blog

|

2027 QPP Final Rule

Finalized Rule for the Quality Payment Program (QPP), including the Merit-based Incentive Payment System (MIPS) and MIPS Value Pathways (MVPs)

CMS recently published the CY 2027 Physician Fee Schedule(PFS) Final Rule which finalized updates for the Quality Payment Program (QPP), including the Merit-based Incentive Payment System (MIPS) and MIPS Value Pathways (MVPs). For the full text of the rule, see the Federal Register.

‍Traditional MIPS

 Quality

For the 2027 performance period, CMS finalized changes to the quality measures inventory resulting in a total of 180 quality measures (177 are available in traditional MIPS and 3 are available only for utilization in MVPs).

·       Addition of 2 quality measures that focus on prevention and chronic disease management (1 is proposed with a 1-yearimplementation delay to the CY 2028 performance period)

·       Adoption of 4 current QCDR measures as MIPS CQMs

·       Replacement of 7 existing, functional improvement MIPS measures with 5 functional outcome measures for orthopedic patients. The 5 new measures were QCDR measures that are finalized as MIPS CQMs.

·       Removal of 20 quality measures

·       Substantive changes to 43 existing measures

 Beginning with the CY 2027 performance period, CMS finalized the removal of the high-priority designation for quality measures. In addition, CMS finalized that MIPS eligible clinicians will no longer be required to report at least one outcome measure as one of their required measures, or a high-priority measure if an applicable outcome measure isn’t available. Instead of reporting an outcome measure (or high-priority measure), CMS finalized that MIPS eligible clinicians are required to report a MIPS core measure as 1 of their 6 quality measures. If a clinician, group, virtual group, subgroup or APM entity does not have an applicable MIPS core measure available to report, the clinician is required to attest there wasn’t an applicable MIPS core measure for them to report and then choose another measure to report in place of the MIPS core measure. Clinicians who fail to report a core measure or complete the self-attestation will receive zero achievement points for that measure.  Small practices are exempt from the MIPS core measure requirement and the self-attestation process.

 CMS finalized that beginning with the CY 2027 performance period, topped out MIPS core measures subject to the 7-point scoring cap will no longer be subject to that cap and will instead be scored according to the defined topped out measure benchmark with a 10-point maximum.

 Cost

There are no proposals to the cost measure inventory for the CY 2027 performance period.

 Improvement Activities

For the CY 2027 performance period, CMS finalized the following updates to the improvement activities inventory:

o   Addition of 6 new activities

o   IA_CC_20: Use of Data to Improve Practice Workflows

o   IA_CC_21: Understand and Improve Diagnostic Performance

o   IA_AHW_2: Systematic Screening and Intervention for Nutrition and other Health-Impacting, Non-Clinical Issues

o   IA_AHW_3: Advance Care Planning Conversations to Support Patient Wellness and Care Preferences

o   IA_AHW_4: Clinician Use of Artificial Intelligence (AI) to Improve Patient Care

o   IA_AHW_5: Lifestyle Approaches to Diabetes Remediation

o   Modification of 5 existing activities

o   IA_BMH_4: Depression screening

o   IA_CC_8: Implementation of documentation improvements for practice/process improvements

o   IA_CC_9: Implementation of practices/processes for developing regular individual care plans

o   IA_PM_4: Glycemic management services

o   IA_PSPA_16: Use decision support—ideally platform-agnostic, interoperable clinical decision support (CDS) tools, including AI-enabled predictive decision-support interventions—and standardized treatment protocols to manage workflow on the care team to meet patient needs

o  Removal of 11 activities

o   IA_BMH_5: MDD prevention and treatment interventions

o  IA_CC_10: Care transition documentation practice improvements

o  IA_CC_11: Care transition standard operational improvements

o  IA_CC_12: Care coordination agreements that promote improvements in patient tracking across settings

o  IA_PSPA_2: Participation in MOC Part IV

o  IA_CC_16: Primary Care Physician and BehavioralHealth Bilateral Electronic Exchange of Information for Shared Patients

o  IA_BE_15: Engagement of Patients, Family, and Caregivers in Developing a Plan of Care

o  IA_PM_19: Glycemic Screening Services

o  IA_PM_20: Glycemic Referring Services

o  IA_EPA_4: Additional improvements in access as aresult of QIN/QIO TA

o  IA_PM_2: Anticoagulant management improvements

Promoting Interoperability

CMS finalized updates to the definition of CEHRT for the Medicare PI Program based on updates proposed by the Office of the National Coordinator for Health IT (ONC). Specifically, CMS removed the certification criteria for “family health history”, “patient health information capture”, “automated numerator recording”, and “automated measure calculation” effective January 1, 2027.  CMS finalized removal of the ONC Direct Review and ONC-Authorized Certification Body (ONC-ACB)Surveillance attestations beginning with the CY 2026 performance period. Also, beginning with CY 2027 performance period, CMS finalized the removal of the Security Risk Analysis measure.

 CMS finalized modifications to the Electronic Prior Authorization measure. For the CY 2027 performance period, CMS finalized that hospitals use CEHRT that includes health IT certified to at least one of the three ONC electronic prior authorization criteria to complete at least one prior authorization request for a medical item or service, excluding drugs. Then, beginning with the CY 2028 performance period, CMS finalized that hospitals are required to use CEHRT that includes health IT certified to all three ONC electronic prior authorization criteria. CMS finalized that the Electronic Prior Authorization measure is optional and eligible for 10 bonus points for the CY2027 performance period and then mandatory beginning with the CY 2028 performance period. A MIPS eligible clinician would be required to attest “Yes” or claim an applicable exclusion, but the measure will not be scored.

 Lastly, CMS finalized a new measure, Electronic Prior Authorization for Prescription Drugs Measure, starting with the CY 2028 performance period. This measure falls under the Health Information Exchange objective and requires the use of specific health IT modules within CEHRT to complete at least one prior authorization request for prescription drugs and medications. A MIPS eligible clinician will be required to attest “Yes” or claim an applicable exclusion, but the measure will not be scored.

 MIPS Value Pathways (MVPs)

 CMS finalized that the traditional MIPS reporting option will be sunset after the CY 2030 performance period. Beginning with CY 2031 performance period, MVPS would be the only MIPS reporting option for MIPS eligible clinicians that do not participate in a MIPS Alternative Payment Model (APM). CMS had proposed CY 2028 as the last year for traditional MIPS but pushed it back 2 years in the final rule.

 For the CY 2027 performance period, CMS finalized 3 new MVPs to the MVP inventory: Diabetic Disease, Hypertension, and Hospitalist. CMS finalized modifications to all 27 existing MVPs. Also, CMS finalized that virtual groups will be able to report an MVP beginning with the CY 2029 performance period. Like in traditional MIPS, CMS finalized that clinicians participating in an MVP will be required to report at least one MIPS core measure as part of their four selected quality measures.

 
Shouldyou have questions or need help with your MIPS/MVPs reporting, please contact us.